cas 40635-66-3|| where to buy 2-Acetoxyisobutyryl chloride

Nom du produit:2-Acetoxyisobutyryl chloride

IUPAC Name:1-chloro-2-methyl-1-oxopropan-2-yl acetate

Unité d'emballage	Stock disponible	Prix($)	Quantité
CM343292-100g	in stock	ĳĳĳ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 40635-66-3 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:40635-66-3; Formule moléculaire:C6H9ClO3; Point de fusion:-; Code SMILES:O=C(Cl)C(C)(OC(C)=O)C; Densité:

: Numéro de catalogue:CM343292; Poids moléculaire:164.59; Point d'ébullition:; N° Mdl:MFCD00000708; Stockage:

: Aliphatic Chain Compounds; Aliphatic chain compounds include aliphatic compounds and chain compounds containing other elements or groups. Aliphatic hydrocarbons are hydrocarbons with the basic properties of aliphatic compounds. In aliphatic compounds, carbon atoms are arranged in straight chain, branched chain or cyclic, which are respectively called straight chain aliphatic hydrocarbons, branched chain aliphatic hydrocarbons and alicyclic hydrocarbons. Some cyclic hydrocarbons are different in nature from aromatic hydrocarbons, and are very similar to aliphatic hydrocarbons. Such cyclic hydrocarbons are called alicyclic hydrocarbons. In this way, aliphatic hydrocarbons become a general term for all hydrocarbons except aromatic hydrocarbons. Aliphatic hydrocarbons and their derivatives (including halogenated hydrocarbons) and alicyclic hydrocarbons and their derivatives are collectively referred to as aliphatic compounds.

: TAK-861; Takeda announced positive topline results from a randomized, double-blind, placebo-controlled, multiple dose Phase 2b trial evaluating TAK-861, an oral orexin receptor 2 (OX2R) agonist, in patients with narcolepsy type 1 and intends to rapidly initiate the first global Phase 3 trials of TAK-861 in first half of fiscal year 2024.